Close Menu

NEW YORK – Healthcare artificial intelligence firm Tempus announced earlier this week the acquisition of Akesogen, the owner of a commercial laboratory and provider of genomics and clinical trial precision medicine services.

Tempus said that the acquisition strengthens its expansion into disease areas outside of cancer and provides it with strategic capabilities in addition to those provided by its Chicago laboratory.

Financial and other terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.